SCHEMBL625882

SCHEMBL625882

C1=NCCNCCNCCNC1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.33
MAPT P10636 1/20 0.33
PDE4A P27815 1/20 0.33
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1780706 1.00 HIF1A (0.33) HIF1AMAPTPDE4AKDR
SCHEMBL1781456 1.00 HIF1A (0.33) HIF1AMAPTPDE4AKDR
SCHEMBL12095338 1.00 HIF1A (0.33) HIF1AMAPTPDE4AKDR
SCHEMBL284489 1.00
SCHEMBL6518187 0.97 HIF1A (0.32) HIF1AMAPTPDE4AKDR
SCHEMBL1782493 0.94
SCHEMBL148995 0.94
SCHEMBL1864746 0.91
SCHEMBL1783195 0.91
SCHEMBL1782807 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1004 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021211-A1 Dual mode radiotracer and -therapeutics UNIV MUENCHEN TECH (DE) 2026-01-22 US claimed
EP-4648800-A1 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME Genmab A/S (DK) 2025-11-19 EP claimed
US-12390540-B2 Dual mode radiotracer and -therapeutics Technische Universität München (DE) 2025-08-19 US claimed
WO-2025034668-A9 LANTHANIDE-BASED CONTRAST AGENTS HAVING IMPROVED STABILITY AND METHODS FOR THEIR PRODUCTION AND PURIFICATION Inventure, LLC (US) 2025-04-03 WO claimed
WO-2025034668-A1 LANTHANIDE-BASED CONTRAST AGENTS HAVING IMPROVED STABILITY AND METHODS FOR THEIR PRODUCTION AND PURIFICATION Inventure, LLC (US) 2025-02-13 WO claimed
US-20250041460-A1 LANTHANIDE-BASED CONTRAST AGENTS HAVING IMPROVED STABILITY AND METHODS FOR THEIR PRODUCTION AND PURIFICATION Inventure, LLC (US) 2025-02-06 US claimed
EP-4291250-B1 DUAL MODE RADIOTRACER AND THERAPEUTICS UNIV MUENCHEN TECH (DE) 2025-01-15 EP claimed
CN-119236123-A HSP 90-targeting conjugates and formulations thereof 融合制药公司 2025-01-03 CN claimed
US-20240399001-A1 RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP) Blue Earth Diagnostics Limited (GB) 2024-12-05 US claimed
CN-119032157-A Microelectronic device cleaning compositions 恩特格里斯公司 2024-11-26 CN claimed
WO-1998042383-A1 CHARGED LIPIDS AND USES FOR THE SAME IMARX PHARMACEUTICAL CORP. (US) 1998-10-01 WO claimed
EP-0545983-B1 INTERMEDIATES FOR CHELATING AGENTS WITH PREFIXED SYMMETRY AND PROCESS FOR THEIR PREPARATION BRACCO SPA (IT) 1994-10-26 EP claimed
US-5354554-A Crosslinked antibodies and processes for their preparation CELLTECH LIMITED (GB) 1994-10-11 US claimed
EP-0433312-A4 CARRIER SYSTEM AND METHOD FOR ENHANCEMENT OF MAGNETIC RESONANCE IMAGING 1991-12-04 EP claimed
EP-0453082-A1 Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent HYBRITECH INCORPORATED (US) 1991-10-23 EP claimed
EP-0433312-A1 CARRIER SYSTEM AND METHOD FOR ENHANCEMENT OF MAGNETIC RESONANCE IMAGING THE UNIVERSITY OF CONNECTICUT (US) 1991-06-26 EP claimed
US-4915933-A Nuclear magnetic resonance THE UNIVERSITY OF NEW MEXICO (US) 1990-04-10 US claimed
WO-1990001900-A1 CARRIER SYSTEM AND METHOD FOR ENHANCEMENT OF MAGNETIC RESONANCE IMAGING THE UNIVERSITY OF CONNECTICUT (US) 1990-03-08 WO claimed
EP-0263861-A1 LYSINE SALT OF THE GADOLINIUM-DOTA COMPLEX AND ITS APPLICATIONS TO DIAGNOSIS. GUERBET SA (FR) 1988-04-20 EP claimed
WO-1987006229-A1 LYSINE SALT OF THE GADOLINIUM-DOTA COMPLEX AND ITS APPLICATIONS TO DIAGNOSIS GUERBET S.A. (FR) 1987-10-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021211-A1 Dual mode radiotracer and -therapeutics FOLH1, SLC19A1, KLK3 HIF1A 424/4885MAPT 3073/4885PDE4A 4822/4885
US-20240399001-A1 RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP) FAP, FIBP, FGFR1 HIF1A 920/4885MAPT 2805/4885PDE4A 2692/4885
US-12390540-B2 Dual mode radiotracer and -therapeutics PAICS, SSTR2, SSTR1 HIF1A 499/4885MAPT 1832/4885PDE4A 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.